Josh Cotts is a Senior Contributor at Game Rant. He graduated Summa Cum Laude from Arizona State University in 2019 with a B.A. in Mass Communications & Media Studies and has been commended since ...

An avid gamer with over 30 years of experience, there aren't many consoles that Dan hasn't owned at some point in his life. He's also part Italian, which means he's almost certainly related to Super ...

The original protagonist gives players the game’s original experience. When choosing protagonists, the game even encourages newcomers to choose the male protagonist because he’s usually considered the ...

This article contains Tenet spoilers. The Protagonist might be one of the most unimaginatively named main characters of all time, but it’s worth pointing out that he is referred to as “the Protagonist ...

GameSpot may get a commission from retail offers. Starfield's protagonist is not voiced, but that wasn't always the case. In pre-production, Bethesda Game Studios wanted to have a voiced protagonist, ...

One of the most interesting parts of anime and shonen protagonists is how many of them seem to share similar traits. Especially within battle series, a vast majority of shonen main characters seem to ...

Ariel and Ursula. Katniss Everdeen and President Snow. Jean Valjean and Javert. Most compelling narratives have a protagonist who the audience is meant to support—and an antagonist who stands in the ...

Matthew Mendisana is a journalist and writer with a passion for storytelling and a love for games and movies. That love carried him through college, while not letting his Autistic Spectrum hold him ...

Takeda is paying Protagonist Therapeutics $300 million upfront to develop and commercialize a late-stage rare hematology asset, inking a pact that gives the California-based biotech the chance to ...

Meet Dev, an avid writer, cat lover, and anime enthusiast. He has a passion for storytelling, traveling, and new adventures. Explore the world of shonen anime through our handpicked selection ...

Johnson & Johnson’s latest prospective offering to the IL-23 psoriasis space—a Protagonist Therapeutics-partnered once-daily oral peptide—has passed a phase 3 checkpoint with results that could pad ...